SITE011-0175

SITE011 (ITA) › SITE011-0175

SITE011-0175

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE011 (ITA) · Dr. Jansen
consented 2026-03-25

enrolled

AEs

4

Serious

0

Dropout signal

–

Adverse events

4

Grade 2 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-02-15 (study day 131); relationship: not assessed

moderate assessed

Grade 1 Aspartate aminotransferase increased — outcome: RECOVERED/RESOLVED; onset 2022-12-18 (study day 72); relationship: not assessed

mild assessed

Grade 2 Colitis — outcome: RECOVERED/RESOLVED; onset 2022-11-22 (study day 46); relationship: not assessed

moderate assessed

Grade 2 Alanine aminotransferase increased — outcome: RECOVERED/RESOLVED; onset 2022-11-18 (study day 42); relationship: RELATED

moderate assessed

Data queries

0

No data queries. Open queries would appear here for this patient.